Wanbangde Pharmaceutical Holding Group Co., Ltd.

SZSE:002082.SZ

6.52 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006200520042003
Revenue 1,541.9391,786.4281,930.60213,701.85615,794.90114,335.3114,635.4589,183.46611,572.19811,451.69411,786.33610,972.92210,873.8668,053.7076,347.7075,835.8684,891.6023,738.9561,172.65535.416416.033
Cost of Revenue 907.265847.299981.87712,348.14115,085.24613,813.03314,409.099,008.63611,389.32411,179.92611,513.55710,732.61910,546.1967,735.5216,085.2435,639.9884,737.7313,616.8211,101.805468.693369.535
Gross Profit 634.674939.129948.7251,353.714709.654522.278226.368174.83182.873271.768272.78240.304327.67318.186262.464195.881153.871122.13570.84566.72346.497
Gross Profit Ratio 0.4120.5260.4910.0990.0450.0360.0150.0190.0160.0240.0230.0220.030.040.0410.0340.0310.0330.060.1250.112
Reseach & Development Expenses 53.98459.10576.196184.891119.72599.60421.7343.35749.55444.50100000000000
General & Administrative Expenses 46.46952.32964.72390.60371.90365.5940.87721.16122.621.57520.20428.68228.23124.32363.89946.39326.34431.43620.0779.7536.611
Selling & Marketing Expenses 280.59398.986393.447436.94283.35770.64930.98731.3234.01172.54958.52435.09140.63336.80934.08825.32918.87112.9988.0024.4682.962
SG&A 327.059451.316458.169527.545155.26136.23971.86452.48156.61194.12478.72863.77268.86461.13397.98671.72245.21544.43528.07914.2219.573
Other Expenses 2.933140.76118.83148.186109.234-2.9021.3896.2175.5553.793.5831.7-0.150.6390.764-1.7071.199-0.727-1.225-0.273-0.774
Operating Expenses 524.273651.181653.195860.622384.219349.327143.808100.787101.013139.474125.924106.545111.347117.517104.19776.52547.68946.32729.64215.60810.694
Operating Income 26.998268.058512.685513.22263.101146.057116.91177.64780.829132.4139.059110.006200.248193.761151.77895.66486.58757.26528.68839.83130.944
Operating Income Ratio 0.0180.150.2660.0370.0170.010.0080.0080.0070.0120.0120.010.0180.0240.0240.0160.0180.0150.0240.0740.074
Total Other Income Expenses Net 2.933-167.925-151.55-165.463-0.518-29.79635.7397.3431.0953.284-5.231-22.053-16.319-6.372-6.038-25.554-18.397-20.667-13.794-11.689-5.882
Income Before Tax 29.932100.133361.135347.757262.583143.155118.29981.38682.955135.578141.625111.706200.005194.297152.2393.80287.78555.8427.43639.49130.045
Income Before Tax Ratio 0.0190.0560.1870.0250.0170.010.0080.0090.0070.0120.0120.010.0180.0240.0240.0160.0180.0150.0230.0740.072
Income Tax Expense 3.60525.81199.97655.54553.75117.96617.8898.00114.52122.22924.36820.76337.54438.82129.15118.25822.76219.0046.87413.6379.81
Net Income 49.20974.323166.51284.936157.02984.0898.21369.73663.025107.531111.55886.409158.644151.986121.04874.04763.61432.8521.38325.67420.235
Net Income Ratio 0.0320.0420.0860.0210.010.0060.0070.0080.0050.0090.0090.0080.0150.0190.0190.0130.0130.0090.0180.0480.049
EPS 0.080.120.270.471.240.350.410.290.260.450.470.360.670.640.510.320.30.230.160.260.21
EPS Diluted 0.080.120.270.471.240.350.410.290.260.450.470.360.670.640.510.320.30.230.160.260.21
EBITDA 209.521375.091607.662620.332397.652240.139141.251142.69150.558199.612215.764199.775272.163257.727208.225158.281140.074106.11356.7358.55946.266
EBITDA Ratio 0.1360.210.3150.0450.0250.0170.010.0160.0130.0170.0180.0180.0250.0320.0330.0270.0290.0280.0480.1090.111